Lexeo Therapeutics is headquartered in New York City, New York. Situated within a major metropolitan biomedical and academic research center, the company leverages its proximity to world-class medical institutions and specialized clinical talent to advance its pipeline of genetic medicines, supported by additional research collaborations and operational infrastructure tailored to genetic and cardiac therapy development.